17 November 2026 | Tuesday | News
Orphalan SA announced the expansion of the TRADITiONAL Study into China, marking the formal randomisation of the first participant into the study globally. TRADITiONAL is an international, multicentre Phase 3 clinical trial evaluating an investigational once-daily formulation of trientine tetrahydrochloride for the first-line treatment of Wilson disease. The study evaluates the safety and efficacy of once-daily trientine tetrahydrochloride compared with D-penicillamine (DPA), an established copper-chelating therapy, over 48 weeks post randomisation.
The global study launched initially in the United States in August 2026 with a progressive activation of sites across the US and the King Faisal Specialist Hospital, Riyadh, Saudi Arabia. Additional sites expected to join this year as global enrolment expands to Pakistan.
This important milestone in China represents the first international study expansion in Wilson disease, with the study's first participant worldwide randomised at The Second Affiliated Hospital of Zhejiang University School of Medicine. Patient recruitment is now actively open across three leading Chinese hospital institutions, with Beijing Friendship Hospital serving as the coordinating lead site:
"The activation of centres in China and the randomisation of our first participant represent a significant milestone in our goal to develop innovative products addressing the current treatment burden of people living with Wilson disease. Our investigational once-daily formulation will be compared with D-penicillamine as a first-line therapy. Current treatment approaches can be complex for people living with Wilson disease. Our goal is to address the unmet patient needs by investigating options that may provide better support for the daily therapeutic management of Wilson disease while maintaining effective copper control." - Omar Kamlin, Chief Medical Officer, Orphalan
Most Read
Bio Jobs
News